OUR MISSION

Advancing skin health through the development of novel therapies for rare dermatologic diseases & itch conditions

OUR SOLUTION

Kamari Pharma is a biopharmaceutical company that is developing novel TRPV3 Inhibitors that may repair the cycle of molecular and local damage in rare dermatologic diseases and itch.

STRATEGIC PIPLINE

We develop topical and oral TRPV3 novel inhibitors for the treatment of Keratoderma and Pruritus causing severe disability and significant reduction in patients’ quality of life. Our Topical formulation is ready for clinical FIH and Oral programs hold great potential to treat severe skin diseases.